RT Generic
T1 Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
A1 Luis Gonzalez-Larriba, Jose
A1 Lazaro-Quintela, Martin
A1 Cobo, Manuel
A1 Domine, Manuel
A1 Majem, Margarita
A1 Garcia-Campelo, Rosario
K1 Epidermal growth factor receptor (EGFR)
K1 tyrosine kinase inhibitor (TKI)
K1 osimertinib
K1 liquid biopsy
K1 rebiopsy
K1 Egfr t790m mutation
K1 Acquired-resistance
K1 Open-label
K1 Phase-iii
K1 1st-line treatment
K1 Met amplification
K1 Carboplatin-paclitaxel
K1 Gefitinib resistance
K1 Gene-mutations
K1 Nsclc patients
AB of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene. EGFR tyrosine kinase inhibitors (EGFR-TKIs) are targeted agents used to treat EGFR mutation-positive advanced NSCLC showing significant improvements in terms of response rate (RR) and progression-free survival (PFS) compared to conventional chemotherapy. However, all patients eventually develop resistance to first-line EGFR-TKIs. The most common mechanism of acquired resistance is the secondary acquisition of a single missense mutation within exon 20 in the EGFR gene, known as the T790M mutation (49-60%). New agents targeting the T790M mutation have undergone clinical development, and among these, osimertinib has shown significant activity in relapsing EGFR mutation positive patients harbouring the T790M mutation. Although precision medicine is a reality for NSCLC, obtaining relevant tissue for repeated molecular analysis from these patients remains a challenge. In this article, a group of experts from the Spanish Society of Medical Oncology (SEOM) and the Spanish Lung Cancer Group (GECP) evaluated the role of rebiopsy and the potential application of plasma-testing methodologies in advanced EGFR mutation patients progressing after EGFR-TKI.
PB Ame publ co
SN 2218-6751
YR 2017
FD 2017-12-01
LK http://hdl.handle.net/10668/19479
UL http://hdl.handle.net/10668/19479
LA en
DS RISalud
RD Apr 6, 2025